ViiV Sees Cabenuva In Adolescents Addressing Adherence, Psychological Distress
Executive Summary
Reducing the frequency of dosing to six times a year instead of daily pills could help reduce some of the psychological trauma teens with HIV face, chief medical officer Harmony Garges told Scrip.
You may also be interested in...
ViiV’s Cabenuva Could Find Niche In Non-Adherent HIV Patients
The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.
Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
ViiV Readies Entry To HIV PrEP Market After Apretude Approval
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.